Pharmacodynamics and pharmacokinetics of extended‐release metformin in patients with type 2 diabetes and chronic kidney disease stage 3B
Abstract
Whereas the immediate-release (IR) formulation of metformin has to be taken two or three times a day, the extended-release (XR) formulation enables once-daily administration and so might help to improve patient adherence, particularly in patients with polypharmacy. Several studies have assessed metformin XR's efficacy, safety, and pharmacokinetics (PK) in healthy people and those with type 2 diabetes (T2D). Many factors affect metformin absorption, disposition and elimination in patients with chronic kidney disease (CKD), leading to metformin accumulation. Although dose adjustment has been simulated using data from metformin XR-treated patients with various levels of kidney function, the pharmacodynamics (PD) and PK of metformin XR in patients with T2D and a defined CKD stage have not previously been studied. We therefore decided to comprehensively assess the efficacy, steady-state PK, and safety of three dose levels of metformin XR in people with T2D and CKD stage 3B.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.